Ross Porter

Dr Ross Porter serves as a CRUK TRACC Clinical Research Training Fellow within the School of Cancer Sciences at the University of Glasgow, focusing on the intersection of inflammatory bowel disease (IBD) and gastrointestinal oncology. His research integrates clinical practice with translational science to address critical gaps in colorectal cancer surveillance and biomarker development for IBD patients.

Porter's research interests center on Inflammatory Bowel Disease-associated colorectal carcinogenesis, with specific expertise in MLH1-deficient cancers, HMGB1 biomarker expression, and immune microenvironment characterization. His work leverages advanced methodologies including QuPath digital pathology algorithms, human tissue-derived organoid models, and immunohistochemical profiling to identify clinically actionable biomarkers for risk stratification and therapeutic targeting.

Analysis of Porter's publication trends reveals a consistent focus on translational GI oncology, with 75% of his recent work examining IBD-cancer connections. Key themes include biomarker validation (HMGB1, c-MET, LL-37), endoscopic surveillance optimization, and organoid-based disease modeling. His research demonstrates strong clinical applicability, particularly in refining surveillance protocols for high-risk IBD populations.

• CRUK TRACC Clinical Research Training Fellowship
• Cancer Research UK Training Fellowship

Porter's research is primarily funded through his CRUK fellowship, which supports his investigation into molecular mechanisms linking chronic inflammation to neoplastic progression. His collaborative work spans multiple institutions across Europe, with significant contributions to multicenter studies like the PORCSE Study on Crohn's disease recurrence. Current projects focus on developing digital pathology tools for automated cancer detection in IBD patients and characterizing immune-cold phenotypes in colorectal cancer.

Porter actively collaborates with the Glasgow Cancer Research UK Centre and participates in tissue-based research using organoid models derived from patient samples. His work interfaces with clinical endoscopy units and pathology departments to validate biomarkers in real-world settings, emphasizing rapid translation from bench to bedside.